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Introduction:We investigated the longitudinal relationship between cortical amyloid
deposition, anxiety, and depression and the risk of incident mild cognitive impairment
(MCI).
Methods: We followed 1440 community-dwelling, cognitively unimpaired individu-
als aged ≥ 50 years for a median of 5.5 years. Clinical anxiety and depression were
assessed using Beck Anxiety and Depression Inventories (BAI, BDI-II). Cortical amy-
loid beta (Aβ) wasmeasured by Pittsburgh compound B positron emission tomography
(PiB-PET) and elevated deposition (PiB+) was defined as standardized uptake value
ratio≥1.48.WecalculatedCoxproportional hazardsmodelswith age as the time scale,
adjusted for sex, education, andmedical comorbidity.
Results: Cortical Aβ deposition (PiB+) independent of anxiety (BAI ≥ 10) or depres-
sion (BDI-II ≥ 13) increased the risk of MCI. There was a significant additive interac-
tion between PiB+ and anxiety (joint effect hazard ratio 6.77; 95% confidence interval
3.58–12.79; P= .031) that is, being PiB+ and having anxiety further amplified the risk
ofMCI.
Discussion:Anxietymodified the association between PiB+ and incidentMCI.
KEYWORDS
amyloid imaging, anxiety, depression,mild cognitive impairment, Pittsburgh compoundBpositron
emission tomography
1 BACKGROUND
Amyloid beta (Aβ) deposition may precede clinical symptoms of
Alzheimer’s disease (AD) by about15 to20years.1,2 The field ofADand
brain aging hasmade substantial advances in biomarkermeasurements
such that in living persons, cortical Aβ deposition can be visualized by
amyloid brain imaging using various types of tracers.3
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Elevated Aβ deposition has been associated with faster cogni-
tive decline in cognitively unimpaired (CU) elderly4–7 and in per-
sons with mild cognitive impairment (MCI).8,9 About 30% of CU and
60% of individuals with MCI are amyloid positron emission tomog-
raphy (PET) positive.1 The use of biomarkers is in line with the
updatedNational InstituteonAging–Alzheimer’sAssociation (NIA-AA)
Research Framework, which recommends a biological definition of AD.
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This includes the “AD continuum,” which can be determined by amyloid
imaging.10
Anxiety and depressive symptoms have also been associated with
cognitivedecline.11–14 Additionally, there is a growingbodyof research
on the association between anxiety, depressive symptoms, and brain
amyloid deposition in brain aging and cognitive decline. For exam-
ple, in cross-sectional studies, we have previously observed a weak
association between cortical amyloid positivity and anxiety as well as
depressive symptoms in CU persons.15 Furthermore, we showed that
the coexistence of MCI with elevated brain amyloid deposition was
associated with higher odds of having anxiety and depression.16 Inves-
tigators from the Australian Imaging, Biomarker & Lifestyle Study of
Ageing (AIBL) observed that elevated anxiety symptoms moderated
the effect of amyloid deposition on cognitive decline in a longitudinal
study.17 However, large-scale longitudinal investigations of the associ-
ation between Aβ deposition, anxiety, depressive symptoms, and MCI
are lacking.
While elevated cortical amyloid deposition is an established
biomarker risk for MCI,7,18 the key point of our analysis was to exam-
ine the relationships between anxiety and depression toMCI riskwhen
amyloid values were available.
Therefore, we conducted a population-based study to examine the
interaction between amyloid deposition and anxiety or depression in
predicting the risk of MCI. We hypothesized that anxiety and depres-
sionwouldmodify the association between cortical amyloid deposition
and incidentMCI in community-dwelling individuals.
2 METHODS
2.1 Setting
The study was conducted in the setting of the population-based Mayo
Clinic Study of Aging (MCSA). We included 1440 CU participants aged
≥ 50 years who underwent baseline neuropsychological testing, Beck
Depression Inventory-II (BDI-II)19 and Beck Anxiety Inventory (BAI)20
assessment, as well as amyloid PET neuroimaging after the base-
line evaluation. Details of the MCSA procedures have been reported
elsewhere.21 Briefly, the MCSA is an ongoing population-based study
examining the prevalence, incidence, and risk factors for MCI and
dementia in Olmsted County, Minnesota. Initially the study was estab-
lished inOctober 2004whenOlmsted County residents, aged 70 to 89
years, were enumerated and an age- and sex-stratified random sam-
ple was invited to participate in the MCSA using the Rochester Epi-
demiology Project (REP) resources.22 As of 2012, recruitment of res-
idents aged 50 to 69 years began, and recruitment is continuing using
the same protocols.
The study was approved by the Mayo Clinic and Olmsted Medical
Center institutional review boards, and informed consent for partici-
pation was obtained from every participant.
HIGHLIGHTS
∙ Weprospectively studied 1440 community-dwelling, non-
demented older persons.
∙ Anxiety modified the association between elevated corti-
cal amyloid beta and incident mild cognitive impairment.
∙ Clinicians should consider anxiety in adults with preclini-
cal Alzheimer’s disease.
RESEARCH INCONTEXT
1. Systematic review: Only a few longitudinal studies have
examined the association between brain amyloid deposi-
tion and anxiety or depression with the outcome of cog-
nitive decline. For example, elevated anxiety symptoms
have been shown tomoderate the effect of amyloid depo-
sition on cognitive decline.
2. Interpretation: While clinical anxiety modified the asso-
ciation between amyloid beta and risk of mild cognitive
impairment (MCI) in cognitively unimpaired (CU) indi-
viduals, depression did not. Therefore, specifically anxi-
ety seems to impact the progression to MCI in amyloid-
positive individuals.
3. Future directions: The findings show the clinical impor-
tance of anxiety in preclinical Alzheimer’s disease (AD).
Even though there is no effective treatment for AD, it
will be crucial to identify high-risk groups at a preclinical
phase to intervene once treatment is available.
More research is needed to examine whether early treat-
ment of anxiety in individuals at high risk for AD might
contribute to prevention or delay of AD
2.2 Study design
This prospective cohort study includedCU individuals onwhomBDI-II,
BAI, and amyloid PET datawere available. Participantswith a diagnosis
of MCI or dementia or missing amyloid PET were excluded. CU partic-
ipants with and without anxiety, depression, or elevated amyloid PET
were followed forward in time for a median of 5.5 years with 95% con-
fidence interval (CI): (5.34, 5.81). The outcome of interest was incident
MCI.23 Cognitive, anxiety, depression, and amyloid datawere available
on 1537 participants, of whom 92 individuals were lost to follow-up
and 5 died. Therefore, the final analyses included 1440CUparticipants
(Figure 1).
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F IGURE 1 Study flowchart. CU, cognitively unimpaired;MCI, mild
cognitive impairment; PiB-PET, amyloid PET imaging using the
Pittsburgh compound B tracer
2.3 Cognitive evaluation
Participants of the MCSA underwent face-to-face evaluations includ-
ing risk factor ascertainment (including BDI-II and BAI) and base-
line evaluation (including Clinical Dementia Rating Scale [CDR])24
performed by a nurse or study coordinator; a neurologic evaluation
including a neurologic interview, Short Test of Mental Status,25 and
neurologic examination performed by behavioral neurologists; and
neuropsychological evaluation of four cognitive domains—memory
(delayed recall trials from the Auditory Verbal Learning Test26 and
the Wechsler Memory Scale–Revised,27 Logical Memory and Visual
Reproduction subtests); language (BostonNaming Test28 and category
fluency); visuospatial (Wechsler Adult Intelligence Scale–Revised,28
PictureCompletion andBlockDesign subtests); and executive function
(Trail Making Test Part B29 and theWechsler Adult Intelligence Scale–
Revised,30 Digit Symbol subtest). All tests were administered by psy-
chometrists and supervised by neuropsychologists. An expert consen-
sus panel of physicians, neuropsychologists, and nurses or study coor-
dinators reviewed the data and determined if a participant was CU or
hadMCI. Classification of CU was based on normative data developed
in this community.31–34
The diagnosis of MCI was based on the revised Mayo Clinic
criteria:23 (1) cognitive concern expressed by a physician, informant,
participant, or nurse; (2) impairment in one or more cognitive domains
(executive functions, memory, language, or visuospatial skills); (3)
essentially normal functional activities; and 4) absence of dementia.
Participants with MCI had a CDR score of 0 or 0.5, but the final diag-
nosis was based on all available data.
2.4 Measurement of anxiety and depression
Participants completed the BDI-II19 and BAI.20 Both inventories are
validated and consist of 21 items that measure common symptoms
of depression over the past 2 weeks, and symptoms of anxiety over
the last week. The severity of each symptom is rated on a Likert scale
ranging from 0 to 3, with a total score ranging from 0 to 63; based
on previous literature a BDI-II cutoff score of ≥13 indicated clinical
depression,35 and aBAI cutoff score of≥10 indicated clinical anxiety.36
2.5 Molecular imaging–PiB-PET acquisition
We performed amyloid PET imaging using the Pittsburgh compound B
(PiB) tracer. Details on PiB-PET imaging in the MCSA have been pub-
lished elsewhere.37–38 Briefly, PiB scans, consisting of four 5-minute
dynamic frames, were acquired from 40 to 60 minutes after intra-
venous injection with 292–728 MBq of 11C-PiB. Images were ana-
lyzed using an in-house, fully automated image processing pipeline in
which image voxel values were extracted from automatically labeled
regions of interest propagated from regions defined on each partici-
pant’s own magnetic resonance imaging (MRI). A global amyloid PET
standardized uptake value ratio (SUVR) was formed from the pre-
frontal, orbitofrontal, parietal, temporal, anterior cingulate, and pos-
terior cingulate/precuneus regions of interest and normalized to the
cerebellar gray matter. Participants with an SUVR ≥ 1.48 (centiloid
22)39 were classified as having an abnormal PiB-PET retention (ele-
vated Aβ burden; PiB+), as beyond that cut-off rates amyloid PET reli-
ably increased.37,40
2.6 Measurement of covariates
We defined the following variables as covariates: age, sex, education,
and medical comorbidity. Comorbid medical conditions were assessed
by the standard Charlson index. The Charlson Comorbidity Index pre-
dicts the 10-year mortality for a patient with a total of 22 potential
comorbid conditions and was calculated using the Deyo method. Thus,
a composite index was calculated after numeric values were assigned
to comorbidmedical conditions.41
2.7 Statistical analysis
We conducted statistical analyses to examine the interaction between
brain amyloid deposition and anxiety or depression in predicting
incident MCI among CU. We calculated hazard ratios (HR) and 95%
CIs using Cox proportional hazards models with age as the time scale,
and adjusted for sex, education, and medical comorbidity. Clinical
depression and clinical anxiety were assessed by the BDI-II (cutoff
score ≥13) and the BAI (cutoff score ≥10), respectively. We used
Kaplan-Meier survival curves for visual display of data, with age as a
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F IGURE 2 Survival curves. BDI±, presence/absence of
depression as measured by Beck Depression Inventory-II; BAI±,
presence/absence of anxiety as measured by Beck Anxiety Inventory;
PiB±, participants with elevated/normal brain amyloid deposition
time scale (Figure 2). We tested for additive interaction as it is more
applicable to biological events than multiplicative interaction.42 In
our models, we compared four groups: PiB–/anxiety– (normal amyloid
deposition/no anxiety; defined as reference group), PiB+/anxiety–
(elevated amyloid deposition/no anxiety), PiB–/ anxiety+ (normal
amyloid deposition/anxiety), and PiB+/ anxiety+ (elevated amyloid
deposition/anxiety); equivalent to anxiety we examined similar groups
using clinical depression. The proportional hazards assumption was
checked for all models by looking at the Schoenfeld residuals; the
assumption was met for all models. Statistical testing was performed
at the conventional two-tailed alpha level of 0.05. All analyses were
performed using SAS System, version 9.4 software (SAS Institute) and
R version 3.6.2 (R Foundation for Statistical Computing).
3 RESULTS
3.1 Demographics
We prospectively followed 1440 CU participants to the outcome of
incident MCI or censoring for a median of 5.5 years; 1061 (73.7%)
persons were PiB-PET–, 379 (26.3%) were PiB-PET+; and 206 partici-
pants (14.3%) developed incidentMCI. Themedian (interquartile range
[IQR]) age was 70.9 (63.0, 77.7) years, 52.8% were males, the median
(IQR) educationwas 15 (13, 17) years and themedian number of medi-
cal comorbiditieswas2 (1, 4) asmeasuredby theCharlsonComorbidity
Index. 41 Themedian (IQR) number of anxiety (asmeasuredbyBAI) and
depressive symptoms (as measured by BDI-II) was 1 (0, 3) and 3 (1, 6),
respectively; 73 (5.1%) participants showed clinical anxiety (BAI ≥ 10),
and 79 (5.5%) clinical depression (BDI-II≥ 13). PiB-PET+ and PiB-PET-
participants differed in terms of age, education, and medical comor-
bidities. BDI-II data were missing for four participants. The complete
demographic characteristics are summarized in Table 1.
3.2 Associations between amyloid positivity and
anxiety/depression with incident MCI
Weexaminedwhether therewas an additive interaction between amy-
loid positivity and clinical anxiety or depression in predicting the risk
of MCI. We defined the reference group as PiB– and no anxiety or
depression, respectively. Compared to the reference group, PiB+ par-
ticipants even in the absence of clinical anxiety (HR [95% CI]): (1.85
[1.38, 2.49],P< .0001) or depression (2.04, [1.52, 2.74],P< .0001)were
at an increased risk of incident MCI. Furthermore, PiB+ participants
with clinical anxiety (HR [95%CI], 6.77 [3.58, 12.79], P< .0001) had an
increased risk of incidentMCI compared to the reference group. There
was a statistically significant additive interactionbetweenamyloid pos-
itivity and clinical anxiety (P = .0310) in increasing the risk of incident
MCI, after adjusting for sex, education, and medical comorbidity. The
interaction between amyloid positivity and clinical depression in pre-
dicting the risk ofMCIwas not statistically significant (Table 2). Initially
we adjusted for sex and education (data not shown); when we addi-
tionally adjusted for medical comorbidity the results were not altered
(Table 2).
4 DISCUSSION
Herein, we report a synergistic additive interaction between elevated
cortical amyloid deposition and clinical anxiety in predicting the risk of
incident MCI. Thus, the combined presence of amyloid positivity and
anxiety was greater than the expected arithmetic sum of their inde-
pendent effects. However, therewas no significant additive interaction
between amyloid positivity and depression.
Additionally, amyloid deposition increased the risk of MCI indepen-
dent of depression and anxiety. Furthermore, PiB+ participants with
clinical anxiety (BAI ≥ 10) had an almost 7-fold increased risk of devel-
opingMCI;whereas being PiB+without clinical anxietywas associated
with almost double the risk; and having clinical anxiety and being PiB–
was not statistically significantly associated with an increased risk of
MCI.
We and others have reported the association between anxiety and
increased risk of MCI13, AD, and vascular dementia.43 However, these
associations between clinical anxiety and risk of dementia are not nec-
essarily etiologic associations. Therefore, studies involving biomarkers
will be crucial to pave the way to understand the mechanism linking
anxiety with risk of dementia.
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TABLE 1 Characteristics of the study cohort at baseline
Variable PiB-PET+ (N= 379)N (%)
PiB-PET– (N= 1061)N
(%) Total (N= 1440)N (%) P
Males 195 (51.5) 565 (53.3) 760 (52.8) <.5467a
Age (years), median [IQR] 76.7 [70.3, 81.9] 68.0 [60.5, 75.7] 70.9 [63.0, 77.7] <.0001b
Education (years), median [IQR] 14 [12, 16] 15 [13, 17] 15 [13, 17] .0229b
Charlson index, median [IQR] 3 [1, 5] 2 [1, 3] 2 [1, 4] <.0001b
BDI-II, median [IQR] 3 [1, 7] 3 [1, 6] 3 [1, 6] .0026b
BDI-II≥ 13 (clinical depression)c 21 (5.6) 58 (5.5) 79 (5.5) .9340a
BAI, median [IQR] 1 [0, 4] 1 [0, 3] 1 [0, 3] 0.6451b
BAI≥ 10 (clinical anxiety) 23 (6.1) 50 (4.7) 73 (5.1) 0.3016a
PiB SUVR, median [IQR] 1.8 [1.6, 2.1] 1.4 [1.3, 1.4] 1.4 [1.3, 1.5] < 0.0001b
Abbreviations: BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory-II; IQR, interquartile range; PiB-PET+, participants with elevated brain amy-
loid deposition; PiB-PET–, participants with normal brain amyloid deposition; PiB SUVR, global amyloid PET standardized uptake value ratio.
Note: P indicates difference between PiB-PET+ and PiB-PET– participants.
ap derived fromChi square test.
bp derived fromWilcoxon rank-sum test.
cBDI-II information is missing on four participants.
TABLE 2 Interaction between brain amyloid deposition and anxiety/depression in predicting the risk of incident mild cognitive impairment
No. at risk No. of events HR (95%CI) P
P for additive
interaction
BAI-Anxiety–/PiB– 1011 95 1.00 (ref. group) 0.0310
BAI-Anxiety+/PiB– 50 4 1.308 (0.479, 3.571) .5999
BAI-Anxiety–/PiB+ 356 96 1.850 (1.376, 2.486) <.0001
BAI-Anxiety+/PiB+ 23 11 6.770 (3.583, 12.791) <.0001
BDI-II Depression–/PiB– 1002 92 1.00 (ref. group) 0.8817
BDI-II Depression+/PiB– 58 7 1.465 (0.677, 3.171) .3321
BDI-II Depression–/PiB+ 355 99 2.037 (1.516, 2.736) <.0001
BDI-II Depression+/PiB+ 21 8 2.266 (1.073, 4.786) .0320
Abbreviations: BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory-II; CI, confidence interval; HR, hazard ratio; PIB-PET–, participants with nor-
mal brain amyloid deposition; PiB-PET+, participants with elevated brain amyloid deposition; ref. group= reference group.
Note: Results based on Cox proportional hazardsmodels, adjusted for age (as the time scale), sex, education, andmedical comorbidity.
Whereasmost studies were limited by small sample sizes and cross-
sectional designs, few studies have examined the longitudinal associa-
tions between cortical amyloid deposition and the outcome of anxiety
or depressive symptoms. For example, investigators fromWashington
University observed that amyloid deposition was associated with
higher depressive symptoms as measured by Geriatric Depression
Scale (GDS) after following 66 CU participants for approximately
1 year.44 Furthermore, investigators from the community-dwelling
Harvard Aging Brain Study (HABS) found that higher baseline amyloid
deposition was associated with increased depressive and particularly
anxious-depressive symptoms as measured by the GDS over a mean of
3.8 years in 270 CU elderly.45
These longitudinal studies examined associations between brain
amyloid deposition and the outcome of anxiety or depressive symp-
toms. However, to date, little is known about anxiety or depression in
modifying the association between amyloid deposition and cognitive
decline.
For example, HABS investigators followed 276 older persons for a
mean of 4.4 years and reported a significant interaction between base-
line amyloid depositionwith higher depressive symptoms (asmeasured
by GDS) on cognitive decline.46 When we examined the association
between amyloid deposition and clinical depression with the outcome
of MCI, we did not find a statistically significant additive interaction
between amyloid positivity and clinical depression in predicting the
risk of MCI. Therefore, in our findings it seems that the addition of
depression to PiB+ did not increase risk over PIB+ alone. Discrepan-
cies in findings might be due tomethodological differences (e.g., differ-
ent assessmentof cognitivedecline anddepression; also, as anxiety and
depressive syndromes often overlap, confounding is possible). Thus, in
the current studywe examined both anxiety and depression separately
and their interaction with PiB+ in increasingMCI risk.
In line with the current study, AIBL investigators conducted a longi-
tudinal study in CU participants examining associations between amy-
loid deposition, depression, and anxiety with the outcome of cognitive
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decline.17 They followed approximately 300 healthy, older adults
(about 50% of AIBL participants had subjective memory complaints
and about 50% were apolipoprotein E [APOE] Ɛ4 carriers) for 54
months and observed that increased amyloid deposition was associ-
ated with increased risk of cognitive decline compared to participants
with negative amyloid imaging. In addition, elevated anxiety symptoms
(as measured by the Hospital Anxiety and Depression Scale [HADS]
score)moderated the effect of amyloid deposition on cognitive decline.
Similar toour findings, they foundno significant impact of depression in
predicting or moderating the effect of amyloid deposition on cognitive
decline.17
Consistent with our results, investigators from Sweden recently
reported anxiety but not depression (as measured by the HADS score)
to interact with amyloid status in predicting faster cognitive decline;
however, they defined cognitive decline solely by Mini-Mental State
Examination.47
Our study replicates these findings and adds to the previous liter-
ature by showing a synergistic additive interaction between elevated
amyloid positivity and anxiety but not depression in predicting the risk
ofMCI in a large population-based sample inwhich extensive cognitive
assessment was available.
While elevated cortical amyloid deposition is an established
biomarker risk forMCI,7,18 we examined the additional impact of anxi-
ety and depression onMCI risk.While anxietymodified the association
between Aβ and risk of MCI in our cohort of CU elderly, depression
did not. Therefore, specifically anxiety seems to impact the early pro-
gression from CU to MCI in amyloid-positive individuals. One possible
explanation could be that anxiety occurs earlier during the preclinical
phase of AD (i.e., AD continuum as defined by PiB+) even before neu-
rodegeneration and cognitive changes occur. This is supported by pre-
vious studies that our group has conducted in the setting of theMCSA,
in which anxiety was a predictor of incident MCI in CU,13 but it did
not predict the risk of dementia in individuals withMCI.14 However, in
these previous studies we did not additionally examine biomarkers like
PiB, which is necessary to define the AD continuum.
Depression on the other hand has been associated with neurode-
generation48–49 and thus could play a more significant role during a
later clinical stage on the AD continuum.
In thepast, our teamhasproposed fourpossible theoretical explana-
tions for the link between neuropsychiatric symptoms and dementia.50
These theoretical constructs can also be applied for clinical anxiety.
They are: (1) the etiologic pathway: anxiety may have a direct delete-
rious effect on the brain, for example via the hypothalamus–pituitary
axis and therefore lead to dementia; in this case anxiety would be con-
sidered a “risk factor”; (2) shared risk factor or confounding pathway:
Aβ, may be the cause of both cognitive decline and anxiety; herein anx-
iety could represent a “disease marker”; (3) a synergistic interaction:
anxiety andAβmayhave a synergistic interaction to further amplify the
risk of incident dementia; and (4) reverse causality: cognitive decline
may lead to reactive anxiety. Importantly, these four theoretical con-
structs are notmutually exclusive and remain hypothetical until empir-
ically validated bymechanistic research.
The current study mostly supports a synergistic interaction
between anxiety and Aβ in increasing the risk of cognitive decline.
Depression on the other hand could be part of the “shared risk factor
or confounding pathway.” In our results it appears that the risk of MCI
in PiB+ depressed individuals is primarily driven by PiB+ and not the
combination of PiB+ and depression althoughwe need to keep inmind
the sample size limitations, as well. Thus depression could be a marker
of amyloid and thus preclinical AD. However anxiety seems to interact
with AD pathology in increasingMCI risk. This association was beyond
the effect of amyloid alone. As we do not know the exact mechanism
more mechanistic research will be needed to explore this interaction
further.
The strengths of our study include the large-scale, population-based
cohort study and a relatively long follow-up time.
Our study also has limitations. Some of the analyzed groups had
relatively low numbers, thus potentially limiting statistical power (for
example, only 8 out of the 21 participants with both depression and
PiB+ developed MCI, and only 11 out of the 23 participants with both
anxiety and PiB+ developedMCI at follow-up). Furthermore only 4 out
of the 50 participants with anxiety and PiB– developed MCI at follow-
up), indicated bywider confidence intervals, which could result in infla-
tion of the point estimates. However, low numbers in some strata are
expected considering that our study sample consisted of community-
dwelling persons. Furthermore, our sample is relatively highly edu-
cated and 98% of study participants are White. However, it has been
shown that data fromOlmstedCounty are generalizable to theUSpop-
ulation of Minnesota and the Upper Midwest,51 even though general-
ization to ethnic minority groups is still limited.
In summary, we expand upon the previous literature by showing
that clinical anxiety in community-dwelling individuals during the pre-
clinical phase of AD increases the risk of incident MCI. Therefore,
anxiety could be a very early marker of AD. Thus, assessing anxiety
could be an important tool to identify patients at high risk of AD even
before cognitive decline occurs. This finding has clinical implications in
that the monitoring and possible management of anxiety among CU
community-dwelling persons with cortical Aβ deposition may be war-
ranted. Even though there is no effective treatment for AD, it will be
crucial to identify high-risk groups at an early preclinical phase to inter-
veneonce treatment is available. Furthermore,with anxiety potentially
modifying the risk of cognitive decline during the preclinical phase of
AD, more research is needed to examine whether early treatment of
anxiety in individuals at high risk for AD might contribute to preven-
tion or delay of AD.
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